Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 18

1.

A decade of adaptation: Regulatory contributions of the World Health Organization to the Global Action Plan for Influenza Vaccines (2006-2016).

Palkonyay L, Fatima H.

Vaccine. 2016 Oct 26;34(45):5414-5419. doi: 10.1016/j.vaccine.2016.07.025. Epub 2016 Aug 3.

2.

Considerations of strategies to provide influenza vaccine year round.

Lambach P, Alvarez AM, Hirve S, Ortiz JR, Hombach J, Verweij M, Hendriks J, Palkonyay L, Pfleiderer M.

Vaccine. 2015 Nov 25;33(47):6493-8. doi: 10.1016/j.vaccine.2015.08.037. Epub 2015 Aug 28. Review.

3.

WHO initiative to increase global and equitable access to influenza vaccine in the event of a pandemic: supporting developing country production capacity through technology transfer.

Friede M, Palkonyay L, Alfonso C, Pervikov Y, Torelli G, Wood D, Kieny MP.

Vaccine. 2011 Jul 1;29 Suppl 1:A2-7. doi: 10.1016/j.vaccine.2011.02.079. Review.

4.

Report of the 6th meeting on the evaluation of pandemic influenza vaccines in clinical trials World Health Organization, Geneva, Switzerland, 17-18 February 2010.

Girard MP, Katz J, Pervikov Y, Palkonyay L, Kieny MP.

Vaccine. 2010 Oct 4;28(42):6811-20. doi: 10.1016/j.vaccine.2010.07.034. Epub 2010 Jul 25.

PMID:
20659520
5.

Report of the fourth meeting on 'Influenza vaccines that induce broad spectrum and long-lasting immune responses', World Health Organization and Wellcome Trust, London, United Kingdom, 9-10 November 2009.

Stephenson I, Hayden F, Osterhaus A, Howard W, Pervikov Y, Palkonyay L, Kieny MP.

Vaccine. 2010 May 21;28(23):3875-82. doi: 10.1016/j.vaccine.2010.03.074. Epub 2010 Apr 14.

PMID:
20398616
6.

WHO meeting on the role of neuraminidase in inducing protective immunity against influenza infection, Vilamoura, Portugal, September 14, 2008.

Bright RA, Neuzil KM, Pervikov Y, Palkonyay L.

Vaccine. 2009 Oct 23;27(45):6366-9. doi: 10.1016/j.vaccine.2009.02.084. No abstract available.

PMID:
19840675
7.

Report of the 5th meeting on the evaluation of pandemic influenza prototype vaccines in clinical trials: World Health Organization, Geneva, Switzerland, 12-13 February 2009.

Hayden FG, Howard WA, Palkonyay L, Kieny MP.

Vaccine. 2009 Jun 24;27(31):4079-89. doi: 10.1016/j.vaccine.2009.04.059. Epub 2009 May 9.

PMID:
19406184
8.

Technology transfer hub for pandemic influenza vaccine.

Friede M, Serdobova I, Palkonyay L, Kieny MP.

Vaccine. 2009 Jan 29;27(5):631-2. doi: 10.1016/j.vaccine.2008.10.080. Epub 2008 Nov 18.

PMID:
19022316
9.

Report of the 4th meeting on the "Evaluation of pandemic influenza prototype vaccines in clinical trials." World Health Organization, Geneva, Switzerland, 14-15 February 2008.

Girard M, Palkonyay L, Kieny MP.

Vaccine. 2008 Sep 15;26(39):4975-7. doi: 10.1016/j.vaccine.2008.04.050. Epub 2008 May 9. No abstract available.

PMID:
18514979
10.

Report of the third meeting on "influenza vaccines that induce broad spectrum and long-lasting immune responses", World Health Organization, Geneva, Switzerland, 3-4 December 2007.

Girard MP, Osterhaus A, Pervikov Y, Palkonyay L, Kieny MP.

Vaccine. 2008 May 12;26(20):2443-50. doi: 10.1016/j.vaccine.2008.03.006. Epub 2008 Mar 28. No abstract available.

PMID:
18420316
11.

Depressive symptoms in early rheumatoid arthritis: a comparative longitudinal study.

Palkonyai E, Kolarz G, Kopp M, Bogye G, Temesvari P, Palkonyay L, Ratko I, Meszaros E.

Clin Rheumatol. 2007 May;26(5):753-8. Epub 2007 Feb 28.

PMID:
17332982
12.

Canadian Association for Immunization Research and Evaluation (CAIRE) guidelines for industry-sponsored clinical trial and epidemiology contract research.

Halperin SA, Scheifele D, Duval B, Law B, Ward B, Bjornson G, Halperin B, Skowronski D, King A, Hammond G, Dobson S, Tamblyn S, Wang E, Lavigne P, Danzig L, Elrick D, Carnan E, Mansi J, Bertrand F, Palkonyay L, Clements G, Maresky N, Wortzman D; Canadian Association for Immunization Research and Evaluation (CAIRE).

Hum Vaccin. 2005 Jul-Aug;1(4):140-2. Epub 2005 Jul 30.

PMID:
17012864
13.

Safety and effectiveness of the new inactivated hepatitis A virus vaccine.

Furesz J, Scheifele DW, Palkonyay L.

CMAJ. 1995 Feb 1;152(3):343-8. Review.

14.

Isolation and uptake characteristics of adenovirus transformed cell revertants resistant to the antiproliferative effects of methylglyoxal bis(guanylhydrazone).

Rodrigues MT, Palkonyay L, Sircar S, Fleurent J, Dessureault J, Weber JM.

Biochem Biophys Res Commun. 1987 Sep 15;147(2):675-81.

PMID:
3632692
15.

Isolation of variants resistant to methylglyoxal bis(guanylhydrazone) from adenovirus-transformed rat cells.

Sircar S, Palkonyay L, Rodrigues M, Allaire S, Horvath J, Thirion JP, Weber J.

Cancer Res. 1987 Mar 1;47(5):1339-43.

16.

Group C adenovirus DNA sequences in human lymphoid cells.

Horvath J, Palkonyay L, Weber J.

J Virol. 1986 Jul;59(1):189-92.

17.

[Structure and functions of cloned adenovirus DNA].

Berencsi G, Palkonyay L, Takács M, Geck P, Anderlik R.

Vopr Virusol. 1986 May-Jun;31(3):346-51. Russian. No abstract available.

PMID:
3020801
18.

Possible causes of the loss of specific pBR322-Ad h 1 DNA recombinants following transfection.

Palkonyay L, Berencsi G, Geck P, Nász I.

Acta Microbiol Hung. 1983;30(3-4):179-88.

PMID:
6372356

Supplemental Content

Loading ...
Support Center